Dr. Medbery is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
535 Wampler Dr
Charleston, SC 29412Phone+1 405-210-7471
Education & Training
- National Capital ConsortiumResidency, Radiation Oncology, 1984 - 1987
- Naval Medical Center (Portsmouth)Residency, Internal Medicine, 1978 - 1980
- Naval Medical Center (San Diego)Internship, Internal Medicine, 1976 - 1977
- Medical University of South CarolinaClass of 1976
Certifications & Licensure
- GA State Medical License 2014 - 2025
- SC State Medical License 1977 - 2025
- IL State Medical License 2014 - 2023
- KY State Medical License 2019 - 2022
- PA State Medical License 1987 - 2022
- OH State Medical License 2014 - 2022
- WV State Medical License 1987 - 2021
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
- American Board of Radiology Radiation Oncology
- Join now to see all
Awards, Honors, & Recognition
- Best Doctors in America Best Doctors, 1995-2015
- Top MD Consumers Checkbook
Clinical Trials
- RSSearch Patient Registry-Long Term Study of Use of SRS/SBRT Start of enrollment: 2012 Mar 01
Publications & Presentations
PubMed
- 6 citationsHigh Dose "HDR-Like" Prostate SBRT: PSA 10-Year Results From a Mature, Multi-Institutional Clinical Trial.Donald B Fuller, Tami Crabtree, Brent L Kane, Clinton A Medbery, Robert Pfeffer
Frontiers in Oncology. 2022-01-01 - 19 citationsPatient and Dosimetric Predictors of Genitourinary and Bowel Quality of Life After Prostate SBRT: Secondary Analysis of a Multi-institutional Trial.Kyle Wang, Ronald C. Chen, Brent L. Kane, Clinton A. Medbery, K. Underhill
International Journal of Radiation Oncology, Biology, Physics. 2018-12-01 - 43 citationsPhase 2 Multicenter Trial of Heterogeneous-dosing Stereotactic Body Radiotherapy for Low- and Intermediate-risk Prostate Cancer: 5-year Outcomes.Donald B. Fuller, Aaron D. Falchook, Tami Crabtree, Brent L. Kane, Clinton A. Medbery
European Urology Oncology. 2018-12-01
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: